BIO 2014: US fears uncertainty over patent eligibility could drive innovation overseas
In a discussion about the implications of the US Supreme Court’s decisions on patent-eligible matter in Prometheus and Myriad at the BIO International Convention yesterday (Wednesday), entitled Patent eligibility from the trenches, an audience member expressed concern that uncertainty over patenting rules could drive American innovators overseas.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
12 June 2025 Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.